Health & Safety Industry Today

Gene Expression Market to Hit $17.96+ Billion by 2031, Exhibiting a 7.7% CAGR

Historical Overview From 2018 to 2020, the gene expression market was analyzed both qualitatively and quantitatively, with significant growth observed in the Asia-Pacific region. This growth was driven by the increasing prevalence of genetic diseases, an aging population, a rise in chronic and acute diseases, heightened awareness of personalized medicine, and the presence of key pharmaceutical and biotechnology companies.
Published 24 June 2024

Market Overview

The global gene expression market was valued at $8,505.71 million in 2021 and is projected to grow to $17,960.77 million by 2031, expanding at a CAGR of 7.7% from 2022 to 2031. Gene expression involves the process where information from a gene is utilized to synthesize a functional gene product, such as a protein or RNA molecule, which are crucial for cellular function. This process includes transcription (DNA to RNA) and translation (RNA to protein), where RNA polymerase helps produce RNA copies of DNA, and the synthesis of proteins is guided by the coding genes (mRNA). Variations in gene expression can occur at several stages, including RNA splicing and post-translational modifications of proteins.

Get a Sample Copy of this Report:

Market Dynamics

Key factors propelling the gene expression market include the rising prevalence of genetic disorders, growing awareness of personalized medicine, and increased application of gene expression in drug discovery. For instance, a CDC report from December 2022 highlighted that various chromosomal defects affected numerous births in the U.S., underscoring the increasing need for gene expression therapies. Additionally, government investments in healthcare infrastructure and R&D activities are crucial for market growth. Technological advancements, like 10x Genomics' targeted gene expression solutions, enhance data analysis and sample throughput, contributing to market expansion.

However, high costs of gene expression instruments and a shortage of skilled professionals pose challenges. Conversely, increased R&D investments in new technologies for tissue- or cell-specific gene expression analysis and a higher prevalence of chronic and genetic diseases present lucrative opportunities for market growth during the forecast period.

Segmental Overview

The gene expression market is segmented by product, application, end-user, and region:

  • By Product: The market includes consumables and instruments, with consumables holding the largest market share due to their extensive use in genetic tests for drug discovery, biomarker discovery, and pharmacogenomics.
  • By Application: Segmented into drug discovery and diagnostics, the diagnostics segment dominates due to the increasing use of gene expression analysis for early and precise diagnosis of rare genetic disorders and chronic illnesses.
  • By End User: The market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and others. Pharmaceutical and biotechnology companies lead the market, leveraging gene expression analysis for drug discovery and development.
  • By Region: North America held the major market share in 2021 and is expected to maintain its dominance, driven by technological advancements, investment in gene expression technology, and extensive R&D activities. Asia-Pacific is expected to grow at the fastest rate, supported by collaborations to enhance healthcare quality and research infrastructure, government funding, and a focus on personalized medicine.

Competition Analysis

Major players in the gene expression market include Illumina Inc., Agilent Technologies, Thermo Fisher Scientific Inc., PerkinElmer Inc., Oxford Nanopore Technologies, QIAGEN, Bio-Rad Laboratories Inc., PacBio, Promega Corporation, and F. Hoffmann-La Roche Ltd. Strategies such as product launches, expansions, and acquisitions are employed to enhance market presence.

Examples of Product Developments

  • Illumina Inc.: Launched the NovaSeq X Series, capable of generating over 20,000 whole genomes annually, enhancing their market position.
  • QIAGEN: Expanded its NGS portfolio with the QIAseq Targeted DNA Pro Panels and QIAseq UPXome RNA Library Kit, setting new standards in nucleic acid sequence preparation.
  • PacBio: Partnered with the Broad Institute and 10x Genomics to launch the MAS-Seq kit, enabling cost-effective long-read single-cell RNA sequencing.
  • Illumina Inc. and AstraZeneca: Formed a strategic research collaboration to accelerate drug target discovery using AI-based genome interpretation and genomic analysis.
  • Thermo Fisher Scientific and Qatar Genome Program: Partnered to advance genomic research and predictive genomics for precision medicine in Arab populations globally.

Enquire Before Buying:

Other Industry News

Ready to start publishing

Sign Up today!